Sign up for email alert when new content gets added: Sign up
No-reflow represents an important limitation of percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Importantly, no-reflow is associated with an increased risk of major adverse cardiac events. In this review, we discuss the pharmacological and nonpharmacological interventions proposed for the prevention and treatment of no-reflow, highlighting the new updates and evidences on efficacy of these approaches.
+441704335730
